Veracyte (VCYT)

• Market cap: $3.17B
• 1 day: 4.66%
• 5 days: -6.11%
• 1 month: 4.31%
• 3 months: 17.40%
• 6 months: 87.91%
• Year to date: 49.23%
• 1 year: 48.96%
• 5 years: 43.37%
• 10 years: 406.06%
• Sector: Healthcare
• Industry: Medical Laboratories

About: Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.

Employees: 815

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

911% more call options, than puts

Call options by funds: $4.58M | Put options by funds: $453K

204% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 25

55% more capital invested

Capital invested by funds: $1.79B [Q2] → $2.78B (+$986M) [Q3]

21% more funds holding

Funds holding: 238 [Q2] → 289 (+51) [Q3]

6% less repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 90

1.29% less ownership

Funds ownership: 108.05% [Q2] → 106.75% (-1.29%) [Q3]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $28 32% downside
• Avg. target: $40 3% downside
• High target: $46 12% upside

7 analyst ratings

• positive: 5 71%
• neutral: 1 14%
• negative: 1 14%

Goldman Sachs Matthew Sykes 64% 1-year accuracy 29 / 45 met price target	10% downside $37	Neutral Downgraded	5 Dec 2024
Morgan Stanley Tejas Savant 33% 1-year accuracy 4 / 12 met price target	32% downside $28	Underweight Maintained	18 Nov 2024
Scotiabank Sung Ji Nam 50% 1-year accuracy 10 / 20 met price target	8% upside $44	Sector Outperform Maintained	8 Nov 2024
UBS Lu Li 100% 1-year accuracy 2 / 2 met price target	13% upside $46	Buy Maintained	7 Nov 2024
Needham Mike Matson 50% 1-year accuracy 58 / 117 met price target	8% upside $44	Buy Maintained	7 Nov 2024